Capivasertib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 258 publications

Salvianolic Acid B Enhances Motor Function Recovery after Spinal Cord Injury in Association with AKT/mTOR/HIF-1α Pathway Activation and Angiogenesis.

Salvianolic Acid B Enhances Motor Function Recovery after Spinal Cord Injury in Association with AKT/mTOR/HIF-1α Pathway Activation and Angiogenesis.

Journal: Biological & pharmaceutical bulletin

Published: August 26, 2026

Corrigendum to "Capivasertib".

Corrigendum to "Capivasertib".

Journal: Hospital pharmacy

Published: July 22, 2026

Early diagnosis of capivasertib-associated severe hyperglycemia with diabetic ketosis diagnosed in routine clinical practice: a case report with review of literature.

Early diagnosis of capivasertib-associated severe hyperglycemia with diabetic ketosis diagnosed in routine clinical practice: a case report with review of literature.

Journal: Endocrine journal

Published: July 01, 2026

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

Journal: Cancer biology & therapy

Published: June 26, 2026

Capivasertib for locally advanced or metastatic breast cancer.

Capivasertib for locally advanced or metastatic breast cancer.

Journal: Australian prescriber

Published: June 18, 2026

Budget impact analysis of capivasertib as a second-line therapy for advanced breast cancer in the United States.

Budget impact analysis of capivasertib as a second-line therapy for advanced breast cancer in the United States.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: June 17, 2026

Early-onset, treatment-cycle-linked hyperinsulinaemic insulin resistance during capivasertib therapy: a case report.

Early-onset, treatment-cycle-linked hyperinsulinaemic insulin resistance during capivasertib therapy: a case report.

Journal: Cardiovascular diabetology. Endocrinology reports

Published: May 25, 2026

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 17, 2026

A spotlight on PTEN alterations in prostate cancer: A narrative review.

A spotlight on PTEN alterations in prostate cancer: A narrative review.

Journal: Critical reviews in oncology/hematology

Published: April 28, 2026

Cost-effectiveness analysis of capivasertib plus fulvestrant in the PIK3CA/AKT1/PTEN-altered subgroup with HR+/HER2- advanced breast cancer: a United States payer perspective.

Cost-effectiveness analysis of capivasertib plus fulvestrant in the PIK3CA/AKT1/PTEN-altered subgroup with HR+/HER2- advanced breast cancer: a United States payer perspective.

Journal: Journal of medical economics

Published: April 20, 2026

PITPβ Drives JAK2 V617F-Mediated Myeloproliferative Neoplasms by Promoting PtdIns(3,4)P ₂ -Dependent AKT Hyperactivation.

PITPβ Drives JAK2 V617F-Mediated Myeloproliferative Neoplasms by Promoting PtdIns(3,4)P ₂ -Dependent AKT Hyperactivation.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer.

Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer.

Journal: JCO precision oncology

Published: April 09, 2026

Showing 1-12 of 258

Last Updated: 09/26/2026